Congratulations: Ribolia Bioscience, Portfolio Company of Yaojin Capital, Successfully Lists on the Hong Kong Stock Exchange

2026Year1Month9Date, Suzhou Ribo Life Science Co., Ltd. (Stock Code:6938) announced its successful listing on the Hong Kong Stock Exchange. As a long-term investor in the company,曜金资本offers its heartfelt congratulations. In this global offering, Ribo Life Science issued a total of3161.0410,000 shares, with an issue price of per share57.97HKD, total fundraising exceeds18HKD. The public offering portion of this IPO was oversubscribed.100Times subscribed, the international offering portion reached16.7The oversubscription reflects global investors' high recognition of the value of the small nucleic acid track and the company's strength. ThisIPOThe funds raised will provide solid financial support for the advancement of the company's core business. Meanwhile, the issuance has introduced China Asset Management, Dacheng International and Dacheng Fund, Taikang Life Insurance, etc.12Heavyweight cornerstone investors at the national level demonstrate the firm confidence of top-tier institutions in the company's long-term prospects.

Ribo Life Science always adheres to the strategy of "innovation-driven, global layout" and深耕RNAInterference (RNAi) technology and small nucleic acid drug research and development for nearly two decades, being one of the earliest pioneers globally to strategically enter this field. The company has built a full-technology-chain self-developed platform covering target discovery, molecular design, delivery technology, process development, and clinical translation, achieving an integrated capability for small nucleic acid drugs from early-stage research to global clinical development. Its innovative liver-targetingRiboGalSTAR^TMDelivery technology has successfully advanced multiple self-developed products targeting cardiovascular, metabolic diseases, and other fields into Phase II clinical trials, with efficacy and safety demonstrating positive clinical validation. Additionally, the company has reached significant agreements with several domestic and international pharmaceutical enterprises, including Boehringer Ingelheim and Qilu Pharmaceutical.BDCollaboration fully demonstrates that its R&D platform and scientific research capabilities have gained international recognition.

The company has established an international R&D and clinical center in Kunshan, Beijing of China, and Gothenburg of Sweden, forming a globally coordinated innovative layout. Among them, the global clinical and business development center located in Gothenburg, SwedenRibocure Pharmaceuticals AB, bringing together an internationally top-tier clinical development team, equipped with advanced R&D facilities, leading the clinical research and commercialization process of the company's global oligonucleotide innovative therapies.

Ribo Life Science's R&D pipeline is both innovative and clinically valuable, with currently...7proprietary drugs have entered the clinical stage, among which4The funds have been advanced to the clinical stage.IIDuring this period, the pipeline thickness and progress firmly rank among the top tier in China. Core products include: the world’s first and fastest clinically advancing targetedFXIThesiRNAAnticoagulant drugsRBD4059; The second product globally to enter clinical trials targetingAPOC3ThesiRNADrugRBD5044; and for the functional cure of chronic hepatitis BsiRNATherapyRBD1016. In addition, the company also has more than20A preclinical project covering multiple fields such as hereditary angioedema, inflammatory diseases, and cancer, has established a diversified and sustainable R&D pipeline.

Dr. Zicai Liang, founder, chairman and CEO of Ribo Life Science, stated: "The listing on the Hong Kong Stock Exchange is an important milestone in the company's development. We sincerely thank global investors for their trust and support. In the future, we will rely on the international capital market to accelerate the global clinical development and commercialization of small nucleic acid drugs, strengthen our technological leadership, bring breakthrough therapies to patients worldwide, and create long-term value for shareholders."

The company's success is inseparable from its R&D team that brings together top professional expertise from around the globe. Liang Zicai, Ph.D., founding chairman and CEO, is a leading pioneer in China’s small nucleic acid technology and pharmaceuticals field, with over20Years of R&D experience and a strong international academic background. Co-CEO Dr. Liming Gan has experience at AstraZeneca.20Years of R&D management experience, having led several major collaborations on nucleic acid drugs. Dr. Zhang Hongyan, the founding president, spearheaded the establishment of the company’s full technology chain R&D system. Core team members mostly come from international pharmaceutical giants such as Pfizer, Bayer, Novartis, and top institutions like Sweden's Karolinska Institutet, covering the entire drug R&D process, providing a solid foundation for the company’s continuous innovation and pipeline advancement.

As the company'sCIn this round of investment, Glory Capital has witnessed the management team, led by Dr. Liang Zicai, guide the company to become a pioneer in China's small nucleic acid drug field. We remain firmly optimistic.RNAiThe long-term value of the track and the company's global development potential. This IPO marks a new starting point for Suzhou Ribo Life Science Co., Ltd., and Yaokin Capital looks forward to the company realizing its innovative potential as soon as possible, bringing more breakthrough treatment options to patients worldwide.

Scan the QR code to follow "Aurora Capital”。